Text

 white paper

New drugs launch despite pandemic and FDA surprises

View the Q3 2020 Drug Pipeline Insights Report

Text

At OptumRx, we are committed to providing our clients, members and the broader healthcare community with up-to-date information and support regarding drug access, cost management and notable FDA approvals.

As expected, we’ve seen some delays in drug development due to COVID-19. Still, new drugs will continue to launch. In this report, we discuss the drugs expected to be approved by the FDA in the months ahead as well as the larger trends to watch this year.

Text

Don't want to read the full report? Download the brief summary.